Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rabeximod - Cyxone

Drug Profile

Rabeximod - Cyxone

Alternative Names: ROB 803

Latest Information Update: 06 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OxyPharma
  • Developer Cyxone
  • Class Acetamides; Disease-modifying antirheumatics; Heterocyclic compounds with 4 or more rings; Small molecules
  • Mechanism of Action Cell differentiation modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis

Most Recent Events

  • 04 Sep 2019 Cyxone plans to subm it orphan drug application for rabeximod
  • 19 Jul 2019 Cyxone enters into an agreement with EGeen to conduct a phase IIb trial for rheumatoid arthritis
  • 19 Jul 2019 Cyxone plans to make regulatory submissions for a phase IIb trial in rheumatoid arthritis to regulatory authority of Estonia, Ukraine, Georgia and the Netherlands within the six months
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top